Arthritis CD56+ NK Cells
Arthritis CD56+ NK Cells are collected from IRB-consented arthritis donors, with the specific arthritis subtype annotated. Ideal for investigating NK cell-mediated inflammation, joint immune infiltration, and altered cytolytic activity across inflammatory and degenerative arthritis.
Arthritis CD56+ NK Cells for Immunology Research
Arthritis CD56+ NK Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with arthritis. These CD56+ CD3− natural killer cells reflect disease-associated immune alterations and support studies of immune surveillance, inflammation, and cytotoxicity.
Which Type of Arthritis Do You Need?
“Arthritis” spans conditions with fundamentally different mechanisms, and NK cell biology differs across them. Specifying the subtype matters more than the cell count:
- Autoimmune inflammatory arthritis — rheumatoid arthritis and psoriatic arthritis, where NK cells accumulate in synovium and contribute to cytokine-driven inflammation
- Degenerative arthritis — osteoarthritis, driven by cartilage breakdown and low-grade rather than autoimmune inflammation
- Crystal arthropathy — gout, where monosodium urate crystals trigger NLRP3 inflammasome and IL-1β-mediated innate activation
- Connective tissue disease with joint involvement — systemic lupus erythematosus, Sjögren’s syndrome, and scleroderma
If your protocol calls for a broad arthritis cohort rather than a single diagnosis, we can assemble a mixed set with each donor’s specific subtype annotated — often the better design for method development, where you want the full analyte range rather than one mechanism.
NK Cells in Arthritis
- Synovial NK accumulation — NK cells are enriched in inflamed joints relative to blood, with a distinct CD56-bright profile
- Altered cytotoxic capacity and activating/inhibitory receptor balance
- Cytokine production — IFN-γ and TNF-α contributing to the inflammatory milieu
- KIR/HLA associations reported in several inflammatory arthritis subtypes
- Treatment effects — biologic therapy measurably alters NK phenotype, so treatment status matters
Donor Stratification Available
- Arthritis subtype — specific diagnosis annotated per donor
- Disease activity — DAS28, CRP, ESR where recorded
- Serostatus — rheumatoid factor and anti-CCP for inflammatory arthritis donors
- Treatment status — treatment-naive, conventional DMARD, or biologic-treated
- Paired specimens — matched synovial fluid, serum, or PBMC from the same donor
- Matched healthy controls available
Product Features
- Research Use Only (RUO), CD56+ enriched NK cells
- Isolated from clinically diagnosed arthritis donors
- High viability and enrichment
- Cryopreserved in CryoStor® CS10 media
- Processed within 24 hours of collection
- Flow cytometry purity and viability data per lot
- Ethically sourced with IRB approval and HIPAA compliance
De-identified Donor Data
- Confirmed diagnosis of arthritis, including subtype
- Demographics: age, sex assigned at birth, race/ethnicity
- Self-reported clinical history and medication use
Applications
- Investigation of NK cell phenotypes and function in arthritis
- Comparative studies across arthritis subtypes
- Cytotoxicity, degranulation, and immune exhaustion assays
- CD56-bright vs CD56-dim subset analysis
- Single-cell analysis and disease mechanism studies
- Biomarker identification and preclinical immunotherapy development
Compliance and Quality Assurance
- IRB-approved collection and 21 CFR Part 11-compliant e-consent
- Standardized processing and quality protocols
- HIPAA-compliant data handling
Ordering & Customization
Arthritis CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD56+ NK cells collection.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom CD56+ NK Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.